Maternal serum IGF-1, IGFBP-1 and 3, and placental growth hormone at 20 weeks' gestation in pregnancies complicated by preeclampsia
journal contributionposted on 08.04.2020, 08:56 by Shutan Liao, Mark H Vickers, Rennae S Taylor, Beatrix Jones, Mhoyra Fraser, Lesley ME McCowan, Philip N Baker, Jo K Perry
Objective To investigate whether maternal serum concentrations of placental growth hormone (GH-V), insulin-like growth factor (IGF) 1 and 2, and IGF binding proteins (IGFBP) 1 and 3 were altered in pregnancies complicated by later preeclampsia (PE). Study design In a nested case-control study, PE cases (n = 71) and matched controls (n = 71) were selected from the Screening for Pregnancy Endpoints (SCOPE) biobank in Auckland, New Zealand. Maternal serum hormone concentrations at 20 weeks of gestation were determined by ELISA. Results We found that maternal serum GH-V concentration at 20 weeks of gestation was unaltered in the PE group, compared to the control group (median, 1.78 ng/ml vs. 1.65 ng/ml, p = 0.884). Maternal IGF-1 and IGFBP-3 concentrations and the IGF-1/IGFBP-3 ratio in PE pregnancies were significantly higher than in controls (median, 253.1 ng/ml vs. 204.3 ng/ml, p < 0.0001; 8535 ng/ml vs. 7711 ng/ml, p = 0.0023; 0.032 vs. 0.026, p < 0.0001, respectively), whereas maternal IGFBP-1 concentration was significantly lower in PE pregnancies than in controls (median, 34.85 ng/ml vs. 48.92 ng/ml, p = 0.0006). Conclusion Our findings suggest a potential role of IGFs and IGFBPs in the prediction of pregnancies complicated by PE. However, the maternal serum concentration of GH-V at 20 weeks’ gestation is unlikely to be useful in the early prediction of PE.
The New Zealand SCOPE study was funded by the New Enterprise Research Fund, Foundation for Research Science and Technology; Health Research Council (04/198); Evelyn Bond Fund, Auckland District Health Board Charitable Trust. This work was funded by The Maurice and Phyllis Paykel Trust and Gravida: National Centre for Growth and Development.
CitationPregnancy Hypertension Volume 10, October 2017, Pages 149-154
VersionAM (Accepted Manuscript)
Published inPREGNANCY HYPERTENSION-AN INTERNATIONAL JOURNAL OF WOMENS CARDIOVASCULAR HEALTH
Pagination149 - 154 (6)
PublisherELSEVIER SCI LTD
Science & TechnologyLife Sciences & BiomedicineObstetrics & GynecologyPeripheral Vascular DiseaseCardiovascular System & CardiologyPlacental growth hormoneInsulin-like growth factorsInsulin-like growth factor binding proteinsPregnancyPreeclampsiaFACTOR BINDING PROTEIN-1UTERINE ARTERY DOPPLERHUMAN TROPHOBLAST INVASIONFACTOR-IBLOOD-PRESSURE2ND TRIMESTERINSULINEXPRESSIONHYPERTENSIONRESISTANCE